Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celsync
- Development stage
- Unknown
- Lead developer
- Glycology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Celsync is an anti-aging dietary supplement developed by Glycology, Inc. It is marketed as a proprietary blend of all-natural nutrients called 'supercarbs' (saccharides) that combine with proteins to form glycoproteins on cell surfaces. The product is based on glycobiology technology and is intended to support cellular communication, immune system function, and potentially help with conditions such as cancer, diabetes, arthritis, chronic fatigue syndrome, and multiple sclerosis. Celsync is available as capsules and is described as safe, non-toxic, and composed of unaltered food elements. It is not a pharmaceutical drug but rather a food supplement.
- Brand names
- Celsync
Beyond the preview
Go deeper on Celsync.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celsync.